Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - azithromycin as dihydrate - powder for solution for infusion - azithromycin as dihydrate 500 mg/vial - azithromycin - azithromycin - treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: community-acquired pneumonia and pelvic inflammatory disease.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - azithromycin as dihydrate - powder for solution for infusion - azithromycin as dihydrate 500 mg/vial - azithromycin - azithromycin - treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: community-acquired pneumonia and pelvic inflammatory disease.

Israel - English - Ministry of Health

mbi pharma ltd., israel - azithromycin as dihydrate - powder for solution for infusion - azithromycin as dihydrate 500 mg - azithromycin - treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: community-acquired pneumonia and pelvic inflammatory disease.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

pharmacare limited û woodmead - powder - see ingredients - each sachet contains saccharomyces boulardii 250,0 mg

Philippines - English - FDA (Food And Drug Administration)

hipra philippines, inc.; distributor: hipra philippines, inc. - inactivated porcine parvovirus , erysipelothrix rhusiopathiae , leptospira interrogans serovar icterohaemorrhagiae , leptospira interrogans serovar canicola , leptospira interrogans serovar pomona , leptospira interrogans serovar hardjo , leptospira interrogans serovar grippotyphosa , leptospira interrogans serovar bratislava vaccine (vet.) - suspension for injection (im) - each 2ml (dose) contains: porcine parvovirus (nadl-2 strain) eryspelothrix rhusiopathiae (r32e11 strain) leptospira interrogans serovar icterohaemorrhagiae leptospira interrogans serovar canicola leptospira interrogans serovar pomona leptospira interrogans serovar hardjo leptospira interrogans serovar grippotyphosa leptospira interrogans serovar bratislava *rp, relative potency (elisa) **iesu (inhibition elisa 50%) mo - microorganisms >1.15* >3.34** 208 mo 10 mo 10 mo 30 mo 10 mo 10 mo

Philippines - English - FDA (Food And Drug Administration)

hipra philippines, inc.; distributor: hipra philippines, inc. - inactivated avibacterium paragallinarum vaccine (vet.) - suspension for injection (im/sc) - formulation: each 0.5 ml (dose) contains: avibacterium paragallinarum, serotype a (17756 strain) ......... > 10^9 microorganisms serotype b (0-222 strain) ........ >10^9 microorganisms serotype c (modesto strain)..... > 10^9 microorganisms

Philippines - English - FDA (Food And Drug Administration)

hipra philippines, inc.; distributor: hipra philippines, inc. - live attenuated canine parvovirus (cpv) , canine distemper virus (cdv) , canine adenovirus type 2 (cav 2) vaccine , inactivated leptospira interrogans ser. icterohaemorrhagiae , l. interrogans ser. canicola vaccine (vet.) - freeze dried powder for injection (sc) - formulation: each ml of reconstituted vaccine (dose) contains: canine parvovirus (c-780916 strain)->10^6 tcid50 canine distemper virus (lederle strain)->10^4 tcid50 canine adenovirus type 2 (manhattan strain)->10^4 tcid50 leptospira interrogans ser. icterohaemorrhagiae->10^9 microorganisms leprospira interrogans ser. canicola toid-tissue culture infactive->10^9 microorganisms

Philippines - English - FDA (Food And Drug Administration)

hipra philippines, inc.; distributor: hipra philippines, inc. - live attenuated canine parvovirus (cpv) , canine distemper virus (cdv) , canine adenovirus type 2 (cav 2) , canine parainfluenza (cpiv) vaccine , leptospira interrogans ser. icterohaemorrhagiae , l. interrogans ser. canicola vaccine (vet.) - freeze dried powder for injection (sc) - formulation: each ml of reconstituted vaccine (dose) contains: canine parvovirus (c-780916 strain)......>10^6 tcid50 canine distemper virus (lederle strain)...........>10^4 tcid50 canine adenovirus type 2 (manhattan strain)............>10^4 tcid50 canine parainfluenza virus (cpiv) (penn 103/70 strain)....... ......>10^5 tcid50 leptospira interrogans ser. icterohaemorrhagiae..........>10^9 microorganisms leptospira interrogans ser. canicola.................. >10^9 microorganisms tcid-tissue culture infective dose

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - clindamycin hydrochloride - capsules - clindamycin hydrochloride 150 mg - clindamycin - clindamycin - treatment of infections caused by susceptible strains of anaerobic microorganisms.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin monohydrate, quantity: 500 mg - capsule, hard - excipient ingredients: dimeticone 350; magnesium stearate; patent blue v; quinoline yellow; titanium dioxide; gelatin; microcrystalline cellulose; carmellose sodium; purified water; shellac; industrial methylated spirit; iron oxide black; 2-ethoxyethanol; dimeticone 1000; lecithin - indications as at 24 february 2004: keflex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. keflex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of keflex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of keflex in the treatment of bacterial infections of the brain and spinal column has not been established and keflex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to keflex. renal function studies should be performed when indicated.